HUMC 1612: Optune NovoTTF-200A System

  • End date
    Sep 18, 2023
  • participants needed
  • sponsor
    Hackensack Meridian Health
Updated on 22 August 2021
platelet count
renal function
karnofsky performance status
glioblastoma multiforme
malignant glioma
anaplastic astrocytoma
tumor progression
astrocytoma, anaplastic
recurrent malignant glioma


The purpose of this study is to determine if the Optune NovoTTF-200A device can be safely used in combination with chemotherapy in pediatric patients with recurrent high-grade glioma and ependemoma.


This phase I trial will utilize a standard 3+3 design to determine the safety and tolerability of the Optune NovoTTF-200A System in pediatric patients with recurrent high-grade glioma end ependemomas.

Patients will receive treatment with the Optune NovoTTF-200A System along with Temozolomide and Bevacizumab and will consist of children with recurrent high-grade gliomas and Ependamomas. Patients enrolled will receive treatment with the Optune NovoTTF-200A with 200kHz for a minimum of 18 hours per day in 28 day cycles as monotherapy. Phase I safety evaluation will take place over the initial two cycles (56 days) of treatment. Following the completion of the safety evaluation period, patients will continue to receive treatment in 28 day cycles, which may be repeated continuously without therapy interruption for 12 cycles or until clinical criteria for discontinuation are met. Patients how appear to benefit from this treatment may be allowed to continue treatment beyond 12 cycles if approved by the study Principle Investigator.

Condition Ependymoma, Glioma, High Grade Glioma, Gliomas, malignant glioma
Treatment bevacizumab, Temozolomide, Optune NovoTTF-200A System
Clinical Study IdentifierNCT03128047
SponsorHackensack Meridian Health
Last Modified on22 August 2021


Yes No Not Sure

Inclusion Criteria

Patients must have a minimum head circumference of 44 cm
Patients must have a histologically- or cytologically-confirmed supratentorial high-grade glioma or supratentorial ependemoma
Patients with metastatic disease involving the infratentorium or spinal cord are eligible providing that they have a supratentorial tumor that is able to be targeted with TTFields
Eligible pathologic diagnoses include
High-grade Glioma (WHO Grade III or IV): Anaplastic Astrocytoma
Astroblastoma, Diffuse Midline Glioma, Glioblastoma, Gliosarcoma Ependymoma
(WHO Grade II or III):Ependymoma, Anaplastic Ependymoma
Patients with high-grade glioma must must have be newly-diagnosed or have a tumor that is progressive or recurrent following standard treatment. Patients with ependymoma must have a tumor that is progressive or recurrent following standard treatment
Patients must have received the maximal feasible resection of their tumor and radiation therapy (unless contraindicated due to patient age) as part of their initial treatment prior to study enrollment
Patients must be enrolled before treatment begins. Treatment must start within 14 days of study enrollment
All clinical and laboratory studies to determine eligibility must be performed within 7 days prior to enrollment unless otherwise indicated in the eligibility section
Newly-diagnosed patients must begin therapy within six weeks of the completion of radiotherapy, or within six weeks of surgical resection if radiotherapy is contraindicated
Recurrent high-grade glioma patients must begin therapy within four weeks of documented tumor progression by MRI scan
Patients must have a Lansky or Karnofsky performance status score of 50%, corresponding to ECOG categories of 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients 16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair will be considered ambulatory for the purpose of assessing the performance score
Able to undergo adequate tumor imaging, via magnetic resonance imaging (MRI) scan to evaluate disease evolution
Adequate hematologic, renal, liver function as demonstrated by laboratory values: ANC 1,000/ul Hemoglobin 8.0 gm/dl Platelet count 100,000/ul
Adequate Liver Function Defined As
Total bilirubin 1.5 x upper limit of normal (ULN) for age, and
SGPT (ALT) < 2.5 x upper limit of normal (ULN) for age. Adequate Renal Function Defined As Either
Creatinine clearance or radioisotope GFR 70ml/min/1.73m2
or a serum creatinine less than or equal to the institutional normal for age
Negative pregnancy test in women of childbearing potential within 7 days of initiating investigational therapy
Recent mothers must agree not to breast feed while receiving medications on study
Patient or legal guardian must give written, informed consent or assent (when applicable)
Able to swallow and ingest oral medication or have a NG or G-tube for drug administration
Urine protein should be screened by urine analysis. If protein 2+ on urinalysis, then Urine Protein Creatinine (UPC) ratio should be calculated. If UPC ratio > 0.5, 24-hour urine protein should be obtained and the level should be < 1000 mg for patient enrollment
Note: UPC ratio of spot urine is an estimation of the 24 urine protein
excretion - a UPC ratio of 1 is roughly equivalent to a 24-hour urine protein
of 1000 mg. UPC ratio is calculated using one of the following formula
[urine protein]/[urine creatinine] - if both protein and creatinine are reported in mg/dL
[(urine protein) x0.088]/[urine creatinine] - if urine creatinine is reported in mmol/L
Adequate Coagulation Defined As: PT/INR 1.5 x upper limit of normal

Exclusion Criteria

Age less than 5 or greater than or equal to 18 years
Head circumference < 44 cm
Absence of supratentorial tumor
Use of any other investigational drug within five half-lives of that drug prior to the initiation of protocol therapy
Anti-cancer therapy within 4 weeks prior to the initiation of protocol therapy (6 weeks for mitomycin and nitrosureas, 4 weeks for curative-intent radiotherapy, and 2 weeks for palliative radiotherapy)
Any National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE version 4.0) >Grade 1 toxicities from prior chemotherapy or radiotherapy that could impact on safety outcome assessment
Any surgery within 14 days prior to initiation of protocol therapy (excluding shunt or line insertion)
Implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator, other implanted electronic devices in the brain, or documented clinically significant arrhythmias
Evidence of increased intracranial pressure (midline shift > 5mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness) Patients receiving escalating doses of corticosteroids to control symptoms of increased intracranial pressure (e.g., require a stable or decreasing dose of corticosteroids for at least 7 days prior to enrollment) will also be excluded
Known > Grade 1 intracranial or intratumoral hemorrhage either by CT or MRI scan within the last 1 month. Patients with resolving hemorrhage changes, punctuate hemorrhage or hemosiderin may enter the study
Pregnant female patients, Pregnancy tests with a negative result must be obtained in all post-menarchal females
Lactating females must agree they will not breastfeed a child while on this study
Males and females of reproductive potential may not participate unless they agree to use an effective contraceptive method and continue to do so for at least 6 months after the completion of therapy
Any serious and/or unstable pre-existing medical, psychiatric or other condition which in the Investigator's opinion could interfere with subject safety, obtaining written informed consent, or compliance with the study protocol
Known hypersensitivity to temozolomide or bevacizumab
Patients who are unable to take oral medications because of significant uncontrolled vomiting will be excluded
Patients must not have a history of myocardial infarction, severe or unstable angina, clinically significant peripheral vascular disease, Grade 2 or greater heart failure, or serious and inadequately controlled cardiac arrhythmia
Patients must not have a known clinically significant bleeding diathesis or coagulopathy
Patients who have experienced arterial thromboembolic events, including transient ischemic attacks or cerebrovascular accidents are excluded from participation
Patients must not have been previously diagnosed with a deep venous thrombosis (including pulmonary embolism), and must not have a known thrombophilic condition (e.g., protein S, protein C, antithrombin III deficiency, Factor V Leiden or Factor II G202'0A mutation, homocysteinemia, or antiphospholipid antibody syndrome)
Patients must not have a history of an abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the last 6 months prior to study entry
Patients with a serious or non-healing wound, ulcer, or bone fracture are not eligible for this study
Patients with a history of allergic reaction to Chinese hamster ovary cell products, or other recombinant human antibodies are ineligible
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note